Immutep Limited ADR (IMMP): Next-Year EPS Estimate 26.75%
As of 2026-10-20, Immutep Limited ADR (IMMP) has a next-year EPS growth estimate of 26.75%. Featured in 4 EPS revision reports, most recently on 2026-10-03.
On 2026-10-19, analyst consensus for IMMP's next-year EPS growth shifted from 25.46% to 26.75% — a positive change of 1.29 percentage points. The revised estimate has been sustained across 2 subsequent trading sessions. Current-year growth is projected at 80.69%.
What's Driving This
The primary
Generated 2026-11-10 from news as of 2026-10-20
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 26.75%
- EPS growth this year
- 80.69%
- EPS next quarter (est)
- -$1.43
- Last price
- $3.29
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-10-20 | 26.75% | 80.69% | -$1.43 | $3.29 |
| 2026-10-19 | 26.75% | 80.69% | -$1.43 | $3.17 |
| 2026-10-16 | 25.46% | 81.03% | -$0.71 | $3.20 |
| 2026-10-15 | 25.46% | 81.03% | -$0.71 | $3.21 |
| 2026-10-14 | 25.46% | 81.03% | -$0.71 | $3.38 |
| 2026-10-13 | 25.46% | 81.03% | -$0.71 | $3.57 |
| 2026-10-12 | 25.46% | 81.03% | -$0.71 | $3.67 |
| 2026-10-11 | 25.46% | 81.03% | -$0.71 | $3.63 |
| 2026-10-10 | 25.46% | 81.03% | -$0.71 | $3.63 |
| 2026-10-09 | 25.46% | 81.03% | -$0.71 | $3.63 |
| 2026-10-08 | 25.46% | 81.03% | -$0.71 | $3.84 |
| 2026-10-07 | 25.46% | 81.03% | -$0.71 | $4.06 |
| 2026-10-06 | 25.46% | 81.03% | -$0.71 | $4.34 |
| 2026-10-05 | 25.46% | 81.03% | -$0.71 | $4.27 |
| 2026-10-04 | 25.46% | 81.03% | -$0.71 | $4.35 |
| 2026-10-03 | 25.46% | 81.03% | -$0.71 | $4.35 |
| 2026-10-02 | 25.46% | 81.03% | -$0.71 | $4.35 |
| 2026-10-01 | 25.46% | 81.03% | -$0.71 | $4.54 |
| 2026-09-30 | 25.46% | 81.03% | -$0.71 | $4.65 |
| 2026-09-29 | 25.46% | 81.03% | -$0.71 | $4.71 |
| 2026-09-28 | 25.46% | 81.03% | -$0.71 | $4.88 |
| 2026-09-27 | 25.46% | 81.03% | -$0.04 | $0.26 |
| 2026-09-01 | 55.66% | -10.49% | -$0.09 | $0.37 |
| 2026-08-31 | 55.66% | -10.49% | -$0.09 | $0.37 |
| 2026-08-30 | 54.98% | 11.82% | -$0.03 | $0.38 |
| 2026-08-29 | 54.98% | 11.82% | -$0.03 | $0.38 |
| 2026-08-28 | 54.98% | 11.82% | -$0.03 | $0.38 |
| 2026-08-27 | 54.98% | 11.82% | -$0.03 | $0.38 |
| 2026-08-26 | 54.98% | 11.82% | -$0.03 | $0.38 |
| 2026-08-25 | 54.98% | 11.82% | -$0.03 | $0.38 |
Reports Featuring IMMP
- 2026-10-03
Immutep ADR Soars 1573% as EPS Growth Estimate Hits 25.5%
- 2026-10-02
Healthcare Stocks Lead: IMMP Surges 1573%, IOVA Jumps 31.7% After EPS Revisions
- 2026-10-01
IMMP Soars 1646% as IOVA, LITE Lead Post-EPS Revision Surge
- 2026-09-30
IMMP Soars 1688% as EPS Revisions Ignite Biotech Rally; IOVA Jumps 37%
Recent News
- Change to American Depositary Share RatioGlobeNewswire
- Immutep Outlines Focused Development Strategy for Eftilagimod Alfa (efti)GlobeNewswire
- Lost Money on Immutep Limited (IMMP)? Possible Fraud - Contact Levi & Korsinsky TodayNewsfile
- Immutep Reports Progress from Phase I Study of LAG-3 Agonist for Autoimmune DiseasesGlobeNewswire
- Immuteps LAG-3 hopes take a hit on Phase III NSCLC terminationClinical Trials Arena
- Adobe downgraded, Nio upgraded: Wall Street's top analyst callsThe Fly
- TACTI-004 Phase III Study in First Line NSCLC to be discontinued following Futility AnalysisGlobeNewswire
- Evotec, Vistagen lay off staff; Immutep shares collapse on study failureBioPharma Dive
- Immutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase III Trial in 1L NSCLCGlobeNewswire
Screen Performance
Aggregate stats across all 2145 tickers our top-EPS-revision screen has flagged over the past 225 days.
- Median return since detection
- -2.9%
- % of tickers in the green
- 43%
- Median return on winners
- +22.8%
- Large revisions captured
- 2246
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
What is Immutep Limited ADR's next-year EPS growth estimate?▾
As of 2026-10-20, Immutep Limited ADR (IMMP) has a next-year EPS growth estimate of 26.75%, based on analyst consensus.
When was the latest EPS estimate revision for IMMP?▾
The most recent revision occurred on 2026-10-19, when analysts adjusted the next-year EPS growth estimate from 25.46% to 26.75%.
What sector and industry does Immutep Limited ADR belong to?▾
Immutep Limited ADR operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. IMMP appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Immutep Limited ADR (IMMP) appears here because it was detected by our daily top-EPS-revision-performer screen.